RxDoctor Payments Data

Markand Patel, MD

Physical Medicine & Rehabilitation · Melbourne, FLNPI 1619266806

Payments from drug & device makers

$3,052in general payments, 2019–2025

Across 95 payments — averaging $32.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$659
  • Medtronic$499
  • Abbott$407
  • Vertiflex, Inc.$243
  • Collegium Pharmaceutical, Inc.$182
  • Amarin Pharma, Inc.$125
  • plus $938 from 21 others

What the payments were for

  • Food & beverage$3,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,052 in reported general payments places this provider in the 85th percentile of 618 physical medicine & rehabilitation providers in Florida.

See all physical medicine & rehabilitation providers in Florida

Medicare billing

Part B allowed, 2024
$1,042,697
Medicare patients
1,545
Services billed
19,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,903$40,825
Xtampza ErOxycodone Myristate61$35,930
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,568$26,815
OxycontinOxycodone Hcl39$18,811
Pregabalin545$18,455
BelbucaBuprenorphine Hcl15$13,568
Hysingla ErHydrocodone Bitartrate19$9,603
Fentanyl82$8,508
Morphine Sulfate ErMorphine Sulfate324$7,082
Oxycodone Hcl352$4,321
Buprenorphine20$3,941
Naloxone Hcl53$3,463
Gabapentin273$2,938
Tramadol Hcl461$2,753
Hydromorphone Hcl100$1,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$182$49,49876 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 618 physical medicine & rehabilitation providers in Florida.

Other physical medicine & rehabilitation in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →